Becton Dickinson (BDX) valuation
Becton Dickinson P/E ratio history
Becton Dickinson trades at 74.5 times its earnings over the last twelve months and 15.1 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 32.2 (year to Sep 2025) to 85.2 (year to Sep 2020), with a median of 41.1.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Sep 30, 2025 | $147.15 | $4.58 | 32.2 | 12.9 |
| Sep 30, 2024 | $189.54 | $4.61 | 41.1 | 17.2 |
| Sep 30, 2023 | $203.25 | $3.88 | 52.3 | 19.6 |
| Sep 30, 2022 | $175.18 | $4.62 | 37.9 | 18.6 |
| Sep 30, 2021 | $188.54 | $5.25 | 35.9 | 19.7 |
| Sep 30, 2020 | $178.46 | $2.09 | 85.2 | — |
| Sep 30, 2019 | $194.02 | $3.02 | 64.2 | — |
| Sep 30, 2018 | $200.18 | $0.34 | n/m | — |
| Sep 30, 2017 | $150.29 | $3.57 | 42.1 | — |
| Sep 30, 2016 | $137.85 | $3.46 | 39.9 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Becton Dickinson valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| Boston ScientificBSX | $62.4B | 17.0 | 13.2 | 3.0 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| StrykerSYK | $112B | 30.2 | 18.6 | 4.3 |
| MedtronicMDT | $124B | 23.8 | 15.9 | 3.3 |
| Peer median | 27.0 | 18.6 | 5.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: BDX financials · BDX returns
No forecast, no recommendation. This page describes Becton Dickinson from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.